Practice
Open Access
Anticraving medication for moderate to severe alcohol use disorder
Jon Mong, Keith Ahamad and Paxton Bach
CMAJ May 10, 2021 193 (19) E695; DOI: https://doi.org/10.1503/cmaj.200895
Jon Mong
Division of General Internal Medicine (Mong), University of Ottawa, Ottawa, Ont.; Departments of Family Practice (Ahamad) and Medicine (Bach), University of British Columbia; British Columbia Centre on Substance Use (Ahamad, Bach), St. Paul’s Hospital, Vancouver, BC
MDKeith Ahamad
Division of General Internal Medicine (Mong), University of Ottawa, Ottawa, Ont.; Departments of Family Practice (Ahamad) and Medicine (Bach), University of British Columbia; British Columbia Centre on Substance Use (Ahamad, Bach), St. Paul’s Hospital, Vancouver, BC
MDPaxton Bach
Division of General Internal Medicine (Mong), University of Ottawa, Ottawa, Ont.; Departments of Family Practice (Ahamad) and Medicine (Bach), University of British Columbia; British Columbia Centre on Substance Use (Ahamad, Bach), St. Paul’s Hospital, Vancouver, BC
MD MScArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Anticraving medication for moderate to severe alcohol use disorder
Jon Mong, Keith Ahamad, Paxton Bach
CMAJ May 2021, 193 (19) E695; DOI: 10.1503/cmaj.200895
Jump to section
- Article
- Anticraving medications help patients to reduce their alcohol consumption by controlling cravings
- Psychosocial interventions should be offered in addition to evidence-based pharmacotherapy
- First-line pharmacotherapy includes naltrexone and acamprosate
- Second-line agents include topiramate and gabapentin
- Anticraving therapies are not a treatment for acute alcohol withdrawal
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
Podcast